Anastasios Manessis is an Endocrinology/Metabolic physician affiliated with Long Island University. OpenAlex indexes 28 publications with 1,523 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
160 E 32nd St
New York, NY 100166004
Telephone
212-675-9332Provider last certified this registry record 2 Jan 2024.
Industry payments
77 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year202565 payments$62,413openpaymentsdata.cms.gov ↗
- Lilly USA, LLCProgram year202574 payments$41,945openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202553 payments$34,052openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
69.3%GLP-1 receptor agonist22.8%Mounjaro52%Ozempic32%Trulicity11%Rybelsus6%Part D≥256 patientsInsulin Analog17.2%Tresiba Flextouch U-10020%Novolog Flexpen13%Lantus Solostar12%Humalog Kwikpen U-10011%Toujeo Solostar7%Basaglar Kwikpen U-1007%Fiasp Flextouch6%Tresiba Flextouch U-2005%Toujeo Max Solostar5%Insulin Lispro Kwikpen U-1003%Lyumjev Kwikpen U-1003%Novolog2%Admelog Solostar2%Soliqua 100-332%Humalog Kwikpen U-2001%Humalog1%Levemir Flexpen1%Insulin Aspart Flexpen1%Apidra Solostar1%Part D<11 patients+ 12 more classes in this area
Cardiovascular
13.4%Statin5.9%Atorvastatin Calcium54%Rosuvastatin Calcium23%Simvastatin15%Pravastatin Sodium5%Livalo3%Part D<11 patientsAngiotensin receptor blocker (ARB)2.1%Losartan Potassium57%Olmesartan-Hydrochlorothiazide9%Valsartan8%Irbesartan6%Olmesartan Medoxomil5%Valsartan-Hydrochlorothiazide5%Cozaar5%Losartan-Hydrochlorothiazide5%Part D<11 patients+ 9 more classes in this area
Hormonal (systemic)
12.7%l-Thyroxine10.9%Levothyroxine Sodium68%Synthroid32%Part D≥257 patientsThyroid Hormone Synthesis Inhibitor1.2%Methimazole100%Part D≥43 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Carsons, MD
Long Island University
Sidney Spector, MD
Long Island University
Reese Wain, MD
Long Island University
Toyooki Sonoda, MD
Long Island University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”